FDA accepts Biohaven’s resubmitted Vyglxia NDA and Baird lifts price target
The U.S. Food and Drug Administration announced acceptance of Biohaven Pharma’s resubmitted new‑drug application for Vyglxia, setting a user‑fee goal date in the first quarter of 2027. Following the filing, Baird raised its price target for Biohaven (BHVN) to $48 from $42 and kept an Outperform rating. Biohaven also entered a licensing agreement with Ono Pharmaceutical that provides $80 million upfront and a $20 million milestone payment for rights to its MoDE IgG degrader portfolio in several Asian markets. The stock jumped as much as 25% after the news.
Why it matters
The higher price target signals Baird’s expectation of increased valuation, which may attract further buying. The licensing deal adds $80 million in near‑term cash and future milestone payments, strengthening Biohaven’s balance sheet.
Key facts
- 1The FDA accepted Biohaven’s resubmitted new‑drug application for Vyglxia and assigned a user‑fee goal date in Q1 2027. finance.yahoo.com
- 2Baird increased its price target for Biohaven to $48, up from $42, and reaffirmed an Outperform rating. investing.com
- 3Biohaven’s licensing agreement with Ono Pharmaceutical provides $80 million upfront and a $20 million milestone payment within a year. finance.yahoo.com
- 4Biohaven’s shares rose as much as 25.02% to close at $14.69 after the FDA filing. finance.yahoo.com
- 5Biohaven’s current stock price was $15.17 at the time of the Baird note. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.